#USA #New York #Securities Fraud #Pomerantz LLP #Immutep Limited

Pomerantz Law Firm Initiates Class Action Against Immutep Limited

Pomerantz LLP has stepped forward to announce a significant legal action against Immutep Limited (NASDAQ: IMMP), marking a critical chapter for investors who have faced considerable losses. The firm has filed a class action lawsuit aimed at addressing allegations of securities fraud and other unlawful business conduct attributed to the company and certain identified officers or directors.

The lawsuit is particularly relevant for those who acquired Immutep securities during a specified period, known as the Class Period. Investors are encouraged to take timely action if they have suffered financially due to the company's reported misconduct. The deadline to apply for appointment as Lead Plaintiff is set for July 6, 2026. Interested parties should reach out to Pomerantz's Danielle Peyton via email or phone and provide relevant details, including their mailing address and the number of shares purchased.

Background of the Case

The impetus for the class action stems from a troubling development that occurred on March 13, 2026. On this date, Immutep announced the recommendation from the Independent Data Monitoring Committee (IDMC) regarding its TACTI-004 Phase III clinical trial. The IDMC advised that the trial evaluating the efficacy of the drug eftilagimod alfa (referred to as 'efti') for patients suffering from non-small cell lung cancer should be discontinued after an interim analysis revealed a lack of efficacy.

Such news is a significant blow to the company, as the abrupt stop in the trial resulted in a staggering 82.44% drop in the value of Immutep's American Depositary Receipts (ADRs), plunging from a previous valuation of approximately $2.27 to a mere $0.48 per share.

This dramatic decline highlights the pressing concerns surrounding the company's communication with investors and the management of expectations regarding ongoing clinical trials.

About Pomerantz LLP

Established for over 85 years, Pomerantz LLP has earned a commendable reputation as a leading firm specializing in corporate, securities, and antitrust class litigations. The firm, founded by Abraham L. Pomerantz, continues his legacy of advocating for investors' rights, particularly in instances involving securities fraud and other corporate misconduct. With global offices in cities like New York, London, Paris, and Tel Aviv, Pomerantz remains committed to pursuing justice for class members, having successfully recovered multimillion-dollar damages over years of dedicated service.

What Investors Should Do

Investors who believe they qualify for this class action are urged to act promptly. Not only is it vital for them to consider their legal standing, but also to participate in holding corporate entities accountable for their actions. Legal representation from a seasoned firm like Pomerantz can strengthen their stance in court and potentially lead to favorable outcomes. Detailed information about the lawsuit and how to join the class can be obtained on Pomerantz's official website.

As the legal proceeding unfolds, it serves as a crucial reminder of the importance of transparency from public companies, especially in the high-stakes world of pharmaceutical development and investor relations.